lorvotuzumab mertansine

Ligand id: 7431

Name: lorvotuzumab mertansine

References
1. Ishitsuka K, Jimi S, Goldmacher VS, Ab O, Tamura K. (2008)
Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy.
Br. J. Haematol., 141 (1): 129-31. [PMID:18279455]
2. Lambert JM. (2013)
Drug-conjugated antibodies for the treatment of cancer.
Br J Clin Pharmacol, 76 (2): 248-62. [PMID:23173552]
3. Lutz RJ, Whiteman KR. (2009)
Antibody-maytansinoid conjugates for the treatment of myeloma.
MAbs, 1 (6): 548-51. [PMID:20068397]
4. Pedersen JT, Searle SMJ, Rees AR, Roguska MA, Guild BC. (1997)
Resurfacing of rodent antibodies.
Patent number: US5639641. Assignee: Immunogen Inc.. Priority date: 09/09/1999. Publication date: 17/06/1997.
5. van de Donk NW, Lokhorst HM. (2013)
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
Expert Opin Pharmacother, 14 (12): 1569-73. [PMID:23721099]
6. Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ. (2014)
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.
MAbs, 6 (2): 556-66. [PMID:24492307]